Scinai Immunotherapeutics Ltd banner

Intrinsic Value

Not Available for 2F50

There is not enough data to reliably calculate the intrinsic value for Scinai Immunotherapeutics Ltd.

Do our valuations actually work? See backtest results .

Alternatives to 2F50

Fundamental Analysis

What Scinai Immunotherapeutics Does

Biotechnology Health Care

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies.

Headquarters
Israel IL
Employees
45
IPO date
Jun 7, 2007
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue 2F50 Research

Decided on Scinai Immunotherapeutics? Get an email when 2F50 reaches the price you’d buy at. Free with an account.

Other Scinai Immunotherapeutics listings

Back to Top